Geovax Labs (GOVX) versus Charles River Laboratories Intl. (CRL) Head to Head Review

Geovax Labs (OTCMKTS:GOVX) and Charles River Laboratories Intl. (NYSE:CRL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Earnings and Valuation

This table compares Geovax Labs and Charles River Laboratories Intl.’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Geovax Labs $960,000.00 498.16 -$2.56 million ($0.02) -86.00
Charles River Laboratories Intl. $2.27 billion 2.83 $226.37 million $6.03 21.83

Charles River Laboratories Intl. has higher revenue and earnings than Geovax Labs. Geovax Labs is trading at a lower price-to-earnings ratio than Charles River Laboratories Intl., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Geovax Labs and Charles River Laboratories Intl., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geovax Labs 0 0 0 0 N/A
Charles River Laboratories Intl. 0 5 10 0 2.67

Charles River Laboratories Intl. has a consensus target price of $144.85, suggesting a potential upside of 10.04%. Given Charles River Laboratories Intl.’s higher probable upside, analysts clearly believe Charles River Laboratories Intl. is more favorable than Geovax Labs.

Institutional & Insider Ownership

0.0% of Geovax Labs shares are owned by institutional investors. Comparatively, 93.9% of Charles River Laboratories Intl. shares are owned by institutional investors. 3.0% of Geovax Labs shares are owned by company insiders. Comparatively, 1.8% of Charles River Laboratories Intl. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Geovax Labs and Charles River Laboratories Intl.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Geovax Labs -266.11% N/A -415.92%
Charles River Laboratories Intl. 9.63% 23.03% 7.70%

Summary

Charles River Laboratories Intl. beats Geovax Labs on 10 of the 12 factors compared between the two stocks.

About Geovax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit